SENDERO HEALTH PLANS

Prior Authorization Request Form	**Infliximab**
Sendero Fax: 512-901-9724	**Phone:** 855-297-9191
URGENCY: ☐ **STANDARD**	☐ **URGENT (In checking this box, I attest to the fact that applying the standard review time frame may seriously jeopardize the customer's life, health or ability to regain maximum function)**

Provider Information	**Patient Information**
Referring/Prescribing Physician: ☐ **PCP** ☐ **Specialist** **Name:** **Please identify SPECIALTY:** **DEA, NPI or TIN:** **Contact:** **Phone: ( ) Fax: ( )**	**Patient's Name:** **Birth Date:** **ID Number:** **Phone Number:** **Patient Height:** **Patient Weight:**
Indicate where the drug is being DISPENSED	**Indicate where the drug is being ADMINISTERED**
☐ **Ambulatory Surgery Center** ☐ **Home Care Agency** ☐ **Inpatient Hospital** ☐ **Long Term Care** ☐ **Outpatient Hospital** ☐ **Patient's Home** ☐ **Pharmacy** ☐ **Physician's Office** ☐ **Other (explain):**	☐ **Ambulatory Surgery Center** ☐ **Inpatient Hospital** ☐ **Long Term Care** ☐ **Outpatient Hospital** ☐ **Patient's Home** ☐ **Pharmacy** ☐ **Physician's Office** ☐ **Other (explain):** **Anticipated Date of Service:**

Approvals may be subject to dosing limits in accordance with FDA-approved labeling, accepted compendia, and/or evidence-based practice guidelines.

PATIENT CLINICAL INFORMATION

CRITERIA QUESTIONS:

1. Is the product being requested for the treatment of an ADULT patient (18 years of age or older) with one of the following indications?

☐ Ankylosing spondylitis (AS), or Peripheral/Axial spondyloarthritis (seronegative spondyloarthropathy)
☐ Crohn's Disease
☐ Psoriasis
☐ Psoriatic arthritis (PsA)
☐ Rheumatoid arthritis (RA)
☐ Ulcerative Colitis
☐ Other: _____

2. What is the prescribed drug?
Preferred: ☐ **Renflexis** ☐ **Inflectra**
Non-preferred: ☐ Remicade ☐ Avsola

3. What is the HCPCS code? _____ What is the ICD-10 code? _____
What is the NDC#: _____

4. Will the requested drug be used in combination with any other biologic or targeted synthetic DMARD (e.g., Olumiant, Xeljanz)? ☐ Yes ☐ No

5. Has the patient had a TB screening test (e.g., a tuberculosis skin test [PPD] or an interferon-release assay [IGRA]) within 6 months of initiating therapy? ☐ Yes ☐ No

6. What were the results of the TB screening test? ☐ Positive ☐ Negative

7. Does the patient have latent or active tuberculosis (TB)? ☐ Latent ☐ Active ☐ No/Neither

8. If the patient has latent or active tuberculosis, has treatment been initiated or completed?
   ☐ Yes - treatment initiated ☐ Yes - treatment completed ☐ No

9. Is this request for continuation of therapy? ☐ Yes ☐ No If No, skip to diagnosis section.

10. For continuation of therapy requests, has the patient achieved or maintained positive clinical response as evidenced by low disease activity or improvement in signs and symptoms since starting treatment with the requested drug? ☐ Yes ☐ No

11. Is the patient currently receiving the requested drug through samples or a manufacturer's patient assistance program? ☐ Yes ☐ No

DIAGNOSIS SECTION ***Please only complete sections below that are relevant to the patient's diagnosis.***

Section A: Crohn's Disease

12. There is documentation of moderate to severe Crohn's disease per the Crohn's Disease Activity index (CDAI):
    ☐ Mild = CDAI <220
    ☐ Moderate = CDAI 220-450
    ☐ Severe = CDAI >450

13. There is documentation of 1 or more of the following high-risk features:
    ☐ Diagnosis at age <30 years
    ☐ Ileal disease
    ☐ Penetrating or stricturing disease
    ☐ Perianal or severe rectal disease
    ☐ Extra-intestinal manifestations
    ☐ History of bowel resections
    ☐ Initial extensive bowel involvement on endoscopy
    ☐ None

14. The treatment is prescribed by or in consultation with a gastroenterologist ☐ Yes ☐ No

15. Has the patient previously received a biologic indicated for Crohn's disease? ☐ Yes ☐ No If Yes, please indicate the drug, duration, response, and intolerance/contraindication if applicable:
    _____

16. Does the patient have perianal or fistulizing Crohn's disease? ☐ Yes ☐ No

17. Has the patient had an inadequate response to a minimum 3 month trial at the maximally indicated dose of 1 or more of the following within the last 6 months?
    If Yes, indicate below and no further questions.
    ☐ Sulfasalazine
    ☐ Mesalamine (if primarily colonic disease)
    ☐ Azathioprine at minimum dose 1.5 mg/kg daily
    ☐ 6-mercaptopurine at minimum dose 50mg daily
    ☐ Methotrexate at minimum dose 15mg IM or SQ weekly
    ☐ Systemic corticosteroids (prednisone, methylprednisolone)
    ☐ None of the above therapies have been trialed

18. Does the patient have a contraindication or intolerance to at least 2 options listed above? ☐ Yes ☐ No
    If yes, please document medications and respective contraindications/intolerances:
    _____

* Please note, the preferred drug in this class is Cimzia, followed by Humira. Please consider prescribing 1 of these drugs before infliximab if clinically appropriately. If infliximab is preferred, please provide additional clinical reasoning documentation here:

_____

Section B. RHEUMATOID ARTHRITIS

19. The patient has diagnosis of rheumatoid arthritis and the treatment is prescribed by or in consultation with a rheumatologist. ☐ Yes ☐ No

20. Has the patient previously received a biologic or targeted synthetic DMARD (e.g., Rinvoq, Xeljanz) that is indicated for moderately to severely active rheumatoid arthritis? ☐ Yes ☐ No If Yes, please indicate the drug, duration, response, and intolerance/contraindication if applicable:_____

21. Has the patient experienced an inadequate response after at least 3 months of treatment with methotrexate 25mg PO weekly* ? ☐ Yes ☐ No If the methotrexate dose is unable to be increased to 25mg PO weekly, please indicate reason: _____

22. Has the patient experienced intolerance to methotrexate? ☐ Yes ☐ No If Yes, indicate intolerance: _____

23. Does the patient have a contraindication to methotrexate? ☐ Yes ☐ No If Yes, indicate contraindication: _____

* Please note, the preferred drug in this class is Cimzia, followed by Simponi, followed by Humira, followed by Enbrel. Please consider prescribing 1 of these drugs before infliximab if clinically appropriately. If infliximab is preferred over these agents, please provide additional clinical reasoning documentation here:_____

Section C: Ulcerative Colitis

24. There is a diagnosis of moderate to severe ulcerative as evidenced by one of the following:
    - ☐ >4 loose and/or bloody bowel movements per day
    - ☐ Evidence of systemic toxicity (e.g., fever, tachycardia, anemia with Hgb<10.0 g/dL, weight loss, and/or elevated CRP or ESR).
    - ☐ Endoscopic findings of marked erythema, absent vascular pattern, friability, erosions, spontaneous bleeding, and/or ulceration (e.g., findings consistent with a Mayo endoscopic sub score of at least 2, or Ulcerative Colitis Endoscopic Index of Severity of at least 5)
    - ☐ Patients with corticosteroid dependent or corticosteroid refractory disease
    - ☐ Patients at high risk for colectomy with clinical documentation of risk by prescribing provider

25. The treatment is prescribed by or in consultation with a gastroenterologist ☐ Yes ☐ No

26. Has the patient previously received a biologic or targeted synthetic disease modifying drug (e.g., Xeljanz) indicated for moderately to severely active ulcerative colitis? ☐ Yes ☐ No If Yes, please indicate the drug, duration, response, and intolerance/contraindication if applicable: _____

27. Has the patient been hospitalized for acute severe ulcerative colitis (e.g., continuous bleeding, severe toxic symptoms, including fever and anorexia)? ☐ Yes ☐ No

28. Has the patient had an inadequate response to a minimum 2 month trial at the maximally indicated dose of 1 or more of the following within the last 6 months?
    If Yes, indicate below and no further questions.
    - ☐ Oral 5-aminosalycylic acid (e.g., sulfasalazine, mesalamine) at a minimum dose of 2g daily
    - ☐ Rectal 5-aminosalycylic acid enemas with minimum dose of 1g daily
        - Note: failure of rectal 5-ASA suppositories alone will not meet criteria for biologic
    - ☐ Budesonide
    - ☐ Thiopurines (e.g., azathioprine, 6-mercaptopurine)
    - ☐ Methotrexate with a minimum dose of 15mg IM or SQ weekly
    - ☐ Systemic corticosteroids (e.g., prednisone, methylprednisolone)
    - ☐ None of the above therapies have been trialed

29. Does the patient have a contraindication or intolerance to at least 2 options listed above? ☐ Yes ☐ No If yes, please document medications and respective contraindications/intolerances: _____

* Please note, the preferred drug in this class is Simponi, followed by Humira. Please consider prescribing 1 of these drugs before infliximab if clinically appropriately. If infliximab is preferred over these drug, please provide additional clinical reasoning documentation here:

_____

Section D: Ankylosing Spondylitis, or Peripheral/Axial Spondyloarthritis (Seronegative Spondyloarthropathy)

30. The patient is diagnosed ankylosing spondylitis or peripheral/axial spondyloarthritis, and the treatment is prescribed by or in consultation with a rheumatologist. ☐ Yes ☐ No

31. Has the patient previously received a biologic indicated for active ankylosing spondylitis? ☐ Yes ☐ No
If Yes, please indicate the drug, duration, response, and intolerance/contraindication if applicable:
_____

32. Has the patient experienced an inadequate response with at least TWO nonsteroidal anti-inflammatory drugs (NSAIDs), or has an intolerance or contraindication to at least two NSAIDs? ☐ Yes ☐ No

* Please note, the preferred drug in this class is Cimzia, followed by Simponi, followed by Humira, followed by Enbrel. Please consider prescribing 1 of these drugs before infliximab if clinically appropriately. If infliximab is preferred over these agents, please provide additional clinical reasoning documentation here:_____

Section E: Psoriasis

33. The patient is diagnosed with psoriasis and treatment is prescribed by or in consultation with a dermatologist or rheumatologist ☐ Yes ☐ No

34. Has the patient previously received Otezla or any other biologic medication indicated for the treatment of moderate to severe plaque psoriasis? ☐ Yes ☐ No If Yes, please indicate the drug, duration, response, and intolerance/contraindication if applicable: _____

35. Has the patient had an inadequate response to 1 or more of the following topical therapies?
    - ☐ Corticosteroids (e.g., betamethasone, clobetasol, desonide) (4-week trial)
    - ☐ Vitamin D analogs (e.g., calcitriol, calcipotriene)
    - ☐ Tazarotene
    - ☐ Calcineurin inhibitors (e.g., tacrolimus, pimecrolimus)
    - ☐ Anthralin
    - ☐ Coal tar

36. Has the patient had an inadequate response to a minimum 3 month trial of methotrexate at a minimum dose of 15mg po weekly within the last 6 months? ☐ Yes ☐ No

37. Does the patient have a contraindication or intolerance to methotrexate? ☐ Yes ☐ No If Yes, indicate contraindication/intolerance and no further questions._____

38. Does the patient have severe psoriasis that warrants a biologic DMARD as first-line therapy (i.e. at least 10% of the body surface area (BSA) or crucial body areas (e.g., hands, feet, face, neck, scalp, genitals/groin, intertriginous areas) are affected)? ☐ Yes ☐ No

* Please note, the preferred drug in this class is Humira, followed by Enbrel. Please consider prescribing 1 of these drugs before infliximab if clinically appropriately. If infliximab is preferred over these agents, please provide additional clinical reasoning documentation here: _____

Section F: PSORIATIC ARTHRITIS

39. The patient is diagnosed with psoriatic arthritis and treatment is prescribed by or in consultation with a rheumatologist ☐ Yes ☐ No

40. Has the patient previously received a biologic medication, apremilast (Otezla), or targeted synthetic DMARD (e.g., Xeljanz) indicated for the treatment of psoriatic arthritis? ☐ Yes ☐ No If Yes, please indicate the drug, duration, response, and intolerance/contraindication if applicable:
    _____

41. Has the patient experienced an inadequate response after at least 3 months of treatment with 1 or more of the following medications at the maximally tolerated dose?
    - ☐ Methotrexate – minimum dose 15mg po weekly
    - ☐ Sulfasalazine – minimum dose 2g po weekly
    - ☐ Cyclosporine
    - ☐ Leflunomide
    - ☐ Apremilast (Otezla)

42. Does the patient have a contraindication or intolerance to at least 2 options listed above? ☐ Yes ☐ No
    If yes, please document medications and respective contraindications/intolerances:
    _____

* Please note, the preferred drug in this class is Cimzia, followed by Simponi, followed by Humira, followed by Enbrel. Please consider prescribing 1 of these drugs before infliximab if clinically appropriately. If infliximab is preferred over these agents, please provide additional clinical reasoning documentation here:
_____

I attest that this information is accurate and true, and that documentation supporting this information is available for review if requested by Sendero Health Plans.	
Prescriber or Authorized Signature	DATE